Insider Shareholders with Direct Ownership of Syros Pharmaceuticals, Inc. (SYRS)
This section provides a comprehensive overview of the insiders with direct ownership of Syros Pharmaceuticals, Inc. (SYRS). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
Syros Pharmaceuticals, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 32,932 | 0 | 33,189 $6,969 | 5 |
Jun 05, 2024
Added 10.76%
|
|
| 16,000 | 0 | 16,000 $3,360 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $3,360 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $3,360 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 16,000 | 0 | 16,000 $3,360 | 3 |
Jun 05, 2024
Added 20.0%
|
|
| 12,000 | 0 | 12,000 $2,520 | 2 |
Jun 01, 2024
Added 25.0%
|
|
| 13,333 | 54,317 | 10,667 $2,240 | 11 |
Sep 16, 2024
Added 20.0%
|
|
| 9,333 | 0 | 9,333 $1,959 | 3 |
Sep 16, 2024
Added 22.23%
|
|
|
Eric R Olson
Chief Scientific Officer |
5,628 | 35,578 | 6,661 $1,398 | 8 |
Jul 17, 2023
Reduced 9.37%
|
| 165,733 | 259,971 | 4,000 $840 | 12 |
Dec 02, 2024
Reduced 90.26%
|
|
|
Mark J Alles
Director |
2,666 | 0 | 3,666 $769 | 1 |
Sep 16, 2023
Added 42.1%
|
|
Jason Haas
Chief Financial Officer |
155,083 | 155,083 | 0 $0 | 12 |
Nov 18, 2024
Reduced 100.0%
|
|
Gerald E Quirk
Chief Legal & Compliance Offic |
55,000 | 63,700 | 0 $0 | 7 |
Nov 19, 2024
Reduced 100.0%
|
|
David Roth
Chief Medical Officer |
55,083 | 88,335 | 0 $0 | 15 |
Nov 18, 2024
Reduced 100.0%
|
|
Conley Chee
President & CEO |
149,666 | 153,666 | 0 $0 | 11 |
Nov 18, 2024
Reduced 100.0%
|
|
Kristin Stephens
Chief Development Officer |
49,666 | 66,869 | 0 $0 | 10 |
Nov 18, 2024
Reduced 100.0%
|